Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jun 22, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat patients with HPV-positive oropharyngeal cancer, which is a type of throat cancer. The researchers want to see if giving a standard dose of chemotherapy along with lower doses of radiation can still effectively control the cancer while reducing side effects. This approach could help patients maintain a better quality of life after their treatment.

To participate in this study, candidates must be generally healthy and have a specific type of throat cancer that is proven to be HPV-positive. Key requirements include having measurable cancer in the throat area and being between the ages of 65 and 74. Participants will receive treatment and will be closely monitored for their health and side effects. The hope is that this less intensive radiation approach will not only control the cancer as well as traditional methods but also lead to fewer long-term side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients generally must have the psychological ability and general health that permits completion of the study requirements and required follow up.
• • Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and until at least 60 days following the last study treatment.
• • Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage).
• • Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving ≤ 4 nodes are permitted and considered as non-therapeutic nodal excisions.
• • Immunohistochemical staining for p16 must be performed on tissue and documented in the pathology report(s) with reported result positive for p16.
• * Clinical stage T1-T3, N0-N2c (AJCC, 7th ed.), which is equal to T1-T3, N0-2 (AJCC, 8th ed.) including no distant metastases based on the following diagnostic workup:
• • General history and physical examination within 30 days prior to registration;
• • Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 60 days prior to registration;
• * One of the following combinations of imaging is required within 45 days prior to registration:
• • 1. A CT scan of the neck (with contrast) and a chest CT scan (with or without contrast);
• • 2. or an MRI of the neck (with contrast) and a chest CT scan (with or without contrast);
• • 3. or a CT scan of neck (with contrast) and a PET/CT of neck and chest (with or without contrast);
• • 4. or an MRI of the neck (with contrast) and a PET/CT of neck and chest (with or without contrast).
• • Note: A CT scan of neck and/or a PET/CT performed for the purposes of radiation planning may serve as both staging and planning tools.
• • Patients will be asked about their personal smoking history prior to enrollment. Only active smokers with greater than 10 pack years will be excluded from the trial. The total number of pack years will be collected at baseline. Current smokers who wish to discontinue will be offered smoking cessation information, and if they are able to discontinue smoking prior to initiation of radiation therapy, they can remain eligible for the trial.
• • Number of pack-years = \[Frequency of smoking (number of cigarettes per day) × duration of cigarette smoking (years)\] / 20 Note: Twenty cigarettes is considered equivalent to one pack. The effect of non-cigarette tobacco products on the survival of patients with p16-positive oropharyngeal cancers is undefined.
• • Zubrod Performance Status of 0-1 within 30 days prior to registration;
• * Adequate hematologic function within 14 days prior to registration, defined as follows:
• • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
• • Platelets ≥ 100,000 cells/mm3;
• • Hemoglobin ≥ 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.
• * Adequate renal function within 14 days prior to registration, defined as follows:
• • Serum creatinine \< 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min
• * Adequate hepatic function within 14 days prior to registration defined as follows:
• • Bilirubin \< 2 mg/dl;
• • AST or ALT \< 3 x the upper limit of normal.
• • Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
• Exclusion Criteria:
• • Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16 positive;
• • Carcinoma of the neck of unknown primary site origin (even if p16 positive);
• • T1-T2 N0-1 lateralized squamous cell carcinoma of the tonsil.
• • Radiographically matted nodes, that span 6 cm or more; N3 disease
• • Supraclavicular nodes, defined as nodes visualized on the same axial imaging slice as the clavicle;
• • Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles;
• • Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease.
• • Simultaneous primary cancers or separate bilateral primary tumor sites;
• • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 5 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible);
• • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;
• • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
• * Severe, active co-morbidity defined as follows:
• • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
• • Transmural myocardial infarction within the last 6 months;
• • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
• • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration;
• • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol other than those requested in Section 3.2.11 of the protocol.